



FOR IMMEDIATE RELEASE

Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces FY 2006 Second Quarter Results

ST. PAUL, MN – February 14, 2006 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter of fiscal year 2006 ended December 31, 2005. The Company was cash flow positive for the quarter, generating cash from operations without the benefit of financing activities. The Company reported a cash balance of \$1,211,717 on December 31, 2005, compared to a reported cash balance of \$1,169,653 as of September 30, 2005.

Revenue for the quarter totaled \$541,106 compared to \$292,015 in the prior year's second quarter ended December 31, 2004, which represents an 85% increase. The Company incurred a net loss of \$283,927 for the quarter or \$(.01) per share compared with a net loss of \$439,768 for the prior year's quarter or \$(.02) per share. Total tests transmitted, a key metric for gauging customer usage, was 7,660 for the quarter, a 63% increase from the prior year's quarterly transmissions.

For the six month period ended December 31, 2005, total revenue was \$922,022, compared to \$545,436 for the same period one year ago, a 69% increase. For the six month period ended December 31, 2005, the Company incurred a net loss of \$621,144, or \$(.02) per share, compared with a net loss of \$874,247, or \$(.03) per share, for the same period one year ago.

"This was a pivotal quarter for the Company," commented CEO Mark Schwartz. "We are beginning to see the results of our team's hard work and the market's acceptance of our technology," added Mr. Schwartz.

The Company has scheduled a conference call to discuss its quarterly financial results on Tuesday, February 14th, at 4:00 PM Central Time. Please contact the Company at 888-687-9999 x106 for conference call information.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2005 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations (Unaudited)

	Three Months Ended December 31		Six Months Ended December 31	
	2005	2004	2005	2004
Revenue:				
Equipment sales	\$ 433,736	\$ 96,870	\$ 685,658	\$ 132,720
Equipment rental	105,614	127,209	227,144	245,357
Service/contract income	1,756	67,936	9,220	167,359
	<u>541,106</u>	<u>292,015</u>	<u>922,022</u>	<u>545,436</u>
Cost of Sales	29,993	52,086	62,493	99,288
Gross Profit	<u>511,113</u>	<u>239,929</u>	<u>859,529</u>	<u>446,148</u>
Expenses:				
Selling, general and administrative	804,239	685,248	1,501,348	1,332,890
Total Expenses	<u>804,239</u>	<u>685,248</u>	<u>1,501,348</u>	<u>1,332,890</u>
Operating Loss	(293,126)	(445,319)	(641,819)	(886,742)
Other Income (Expense):				
Interest income	9,199	5,551	20,675	12,495
Net Loss	<u>\$ (283,927)</u>	<u>\$ (439,768)</u>	<u>\$ (621,144)</u>	<u>\$ (874,247)</u>
Basic and Diluted Net Loss per Share	\$ (.01)	\$ (.02)	\$ (.02)	\$ (.03)
Weighted Average Shares Outstanding	33,264,362	27,092,385	33,097,633	27,047,157

Balance Sheet Data

	December 31, 2005 (Unaudited)	June 30, 2005 (Audited)
Cash and cash equivalents	\$ 1,211,717	\$ 1,525,865
Total current assets	1,623,942	1,962,747
Total assets	1,771,595	2,193,866
Total current liabilities	661,602	574,671
Accumulated deficit	(25,326,721)	(24,705,577)
Total shareholders' equity	1,098,037	1,603,537

#

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdii.com